Treatment with pentoxifylline and ciprofloxacin reduces the toxicity of high-dose interleukin-2 and lymphokine-activated killer cells.
Thompson
J A
JA
Department of Medicine, University of Washington School of Medicine, Seattle.
Benyunes
M C
MC
Bianco
J A
JA
Fefer
A
A
D002292:Carcinoma, Renal Cell / Q000556:secondary / Q000628:therapy*; D002939:Ciprofloxacin / Q000008:administration & dosage / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004359:Drug Therapy, Combination; D006801:Humans; D016219:Immunotherapy, Adoptive / Q000379:methods; D007376:Interleukin-2 / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D007680:Kidney Neoplasms / Q000628:therapy*; D015979:Killer Cells, Lymphokine-Activated; D010431:Pentoxifylline / Q000008:administration & dosage / Q000627:therapeutic use*; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use
D007376:Interleukin-2; D011994:Recombinant Proteins; D002939:Ciprofloxacin; D010431:Pentoxifylline